Hemochromatosis - Pipeline Insight, 2021
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Hemochromatosis – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemochromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hemochromatosis: Overview
Hemochromatosis is the abnormal accumulation of iron in parenchymal organs, leading to organ toxicity. It is the most common autosomal recessive genetic disorder and the most common cause of severe iron overload. There are two types of hemochromatosis, each with different causes. An inherited genetic change is the most common cause. It’s called primary hemochromatosis, hereditary hemochromatosis or classical hemochromatosis. With primary hemochromatosis, problems with the DNA come from both parents and cause the body to absorb too much iron. In secondary hemochromatosis, medical treatments or other medical conditions cause the iron overload. Men have hemochromatosis more than women. Women lose iron when they get their periods or have babies. Not every person with hemochromatosis develops symptoms. Some people with high levels of iron don’t have any problems, while others experience very serious symptoms. Symptoms usually don’t appear until middle age, and they often look like signs of other conditions. Diagnosis for hemochromatosis is based on blood tests to check levels of iron and certain proteins in the blood and to check for gene mutations that commonly cause hemochromatosis. Treatment of hemochromatosis is done with phlebotomy, or drawing about a pint of blood at a time, on a regular schedule. Another option is chelation. This is a developing therapy that can help manage iron levels, but it is expensive and not a first-line treatment option.
'Hemochromatosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemochromatosis pipeline landscape is provided which includes the disease overview and Hemochromatosis treatment guidelines. The assessment part of the report embraces, in depth Hemochromatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemochromatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Hemochromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hemochromatosis Emerging Drugs
Further product details are provided in the report……..
Hemochromatosis: Therapeutic Assessment
This segment of the report provides insights about the different Hemochromatosis drugs segregated based on following parameters that define the scope of the report, such as:
Hemochromatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemochromatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemochromatosis drugs.
Hemochromatosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Hemochromatosis – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemochromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hemochromatosis: Overview
Hemochromatosis is the abnormal accumulation of iron in parenchymal organs, leading to organ toxicity. It is the most common autosomal recessive genetic disorder and the most common cause of severe iron overload. There are two types of hemochromatosis, each with different causes. An inherited genetic change is the most common cause. It’s called primary hemochromatosis, hereditary hemochromatosis or classical hemochromatosis. With primary hemochromatosis, problems with the DNA come from both parents and cause the body to absorb too much iron. In secondary hemochromatosis, medical treatments or other medical conditions cause the iron overload. Men have hemochromatosis more than women. Women lose iron when they get their periods or have babies. Not every person with hemochromatosis develops symptoms. Some people with high levels of iron don’t have any problems, while others experience very serious symptoms. Symptoms usually don’t appear until middle age, and they often look like signs of other conditions. Diagnosis for hemochromatosis is based on blood tests to check levels of iron and certain proteins in the blood and to check for gene mutations that commonly cause hemochromatosis. Treatment of hemochromatosis is done with phlebotomy, or drawing about a pint of blood at a time, on a regular schedule. Another option is chelation. This is a developing therapy that can help manage iron levels, but it is expensive and not a first-line treatment option.
'Hemochromatosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hemochromatosis pipeline landscape is provided which includes the disease overview and Hemochromatosis treatment guidelines. The assessment part of the report embraces, in depth Hemochromatosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemochromatosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hemochromatosis R&D. The therapies under development are focused on novel approaches to treat/improve Hemochromatosis.
This segment of the Hemochromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hemochromatosis Emerging Drugs
- PTG-300: Protagonist Therapeutics
Further product details are provided in the report……..
Hemochromatosis: Therapeutic Assessment
This segment of the report provides insights about the different Hemochromatosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hemochromatosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Hemochromatosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemochromatosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemochromatosis drugs.
Hemochromatosis Report Insights
- Hemochromatosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hemochromatosis drugs?
- How many Hemochromatosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemochromatosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hemochromatosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hemochromatosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Hemochromatosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
PTG-300: Protagonist Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
DISC-A: Disc Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Hemochromatosis Key Companies
Hemochromatosis Key Products
Hemochromatosis- Unmet Needs
Hemochromatosis- Market Drivers and Barriers
Hemochromatosis- Future Perspectives and Conclusion
Hemochromatosis Analyst Views
Hemochromatosis Key Companies
Appendix
Executive Summary
Hemochromatosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
PTG-300: Protagonist Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
DISC-A: Disc Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Hemochromatosis Key Companies
Hemochromatosis Key Products
Hemochromatosis- Unmet Needs
Hemochromatosis- Market Drivers and Barriers
Hemochromatosis- Future Perspectives and Conclusion
Hemochromatosis Analyst Views
Hemochromatosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hemochromatosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hemochromatosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hemochromatosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hemochromatosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products